AKESO Shares Surge Nearly 8% in Morning Session as First-in-Class Trispecific Antibody AK150 Enters Clinical Trials

Stock News03-10

AKESO (09926) saw its stock rise nearly 8% during the morning trading session. As of the time of writing, the share price had increased by 7.33% to HK$111.3, with a trading volume of HK$276 million. The surge follows the announcement that AK150, the company's first-in-class trispecific antibody drug targeting ILT2, ILT4, and CSF1R, has received implicit approval for clinical trials from the Center for Drug Evaluation of the National Medical Products Administration. The drug will now advance into clinical studies for the treatment of advanced malignant solid tumors. Public information indicates that AK150 is the only ILT2/ILT4/CSF1R trispecific antibody currently under development globally and represents AKESO's first trispecific antibody to enter the clinical stage. Developed using the company's advanced AI-driven drug discovery platform and Tetrabody multispecific antibody technology, AK150 underscores AKESO's strong capabilities in the field of multispecific antibody therapeutics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment